

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Technical Evaluation Panel (TEP): Pilot Follow-Up of Former Workers at Vermiculite Processing Sites in the United States, Contract Solicitation Number #0000HTB8-2005-19635

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Technical Evaluation Panel (TEP): Pilot Follow-Up of Former Workers at Vermiculite Processing Sites in the United States, Contract Solicitation Number #0000HTB8-2005-19635.

Times and Dates: 11:30 a.m.–12 p.m., July 7, 2005 (Open); 12 p.m.–3 p.m., July 7, 2005 (Closed).

Place: Teleconference (404) 498-0003.

Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to: Pilot Follow-Up of Former Workers at Vermiculite Processing Sites in the United States, Contract Solicitation Number #0000HTB8-2005-19635.

Contact Person for More Information: Mildred Williams-Johnson, Ph.D., D.A.B.T., Health Science Administrator, National Center for Environmental Health, CDC, 1600 Clifton Road NE., Mailstop E28, Atlanta, GA 30333, Telephone (404) 498-0639.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 16, 2005.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 05-12296 Filed 6-21-05; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following Federal Committee meeting.

Name: Advisory Committee on Immunization Practices (ACIP).

Times and Dates: 8 a.m.–6:45 p.m., June 29, 2005; 8 a.m.–3:35 p.m., June 30, 2005.

Place: Atlanta Marriott Century Center, 2000 Century Boulevard, NE., Atlanta, Georgia 30345-3377.

Status: Open to the public, limited only by the space available.

Purpose: The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.

Matters To Be Discussed: The agenda will include discussions on pertussis adolescent recommendation and use in adults; Hepatitis B vaccine recommendation; recommendations of use of Hepatitis A vaccine and possible VFC vote; Measles, Mumps, Rubella, and Varicella Virus Vaccine (MMRV); Overview of varicella epidemiology and possible VFC votes on second dose varicella and MMRV; summary of American Academy of Pediatrics recommendations; Human Papilloma Virus vaccine working group update; general recommendations: vaccine storage and handling; adult immunization schedule; Advisory Committee on Immunization Practices and National Vaccine Advisory Committee joint working group and the preliminary results on pandemic vaccine prioritization; Advisory Committee on Immunization Practices and Healthcare Infection Control Practices Advisory Committee joint statement on immunization of health care workers against influenza; rotavirus; HIV vaccine update; and Departmental updates.

Contact Person for more Information: Demetria Gardner, Epidemiology and Surveillance Division, National Immunization Program, CDC, 1600 Clifton Road, NE., (E-61), Atlanta, Georgia 30333, telephone 404/639-8096, fax 404/639-8616.

Due to programmatic issues that had to be resolved, the **Federal Register** notice is being published less than fifteen days before the date of the meeting.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and

other committee management activities for both the CDC and ATSDR.

Dated: June 16, 2005.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 05-12293 Filed 6-21-05; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Institute for Occupational Safety and Health Advisory Board on Radiation and Worker Health

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), and pursuant to the requirements of 42 CFR 83.15(a), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

Name: Advisory Board on Radiation and Worker Health (ABRWH), National Institute for Occupational Safety and Health (NIOSH) and Subcommittee for Dose Reconstruction and Site Profile Reviews.

Subcommittee Meeting Times and Dates: 7:30 a.m.–8:30 a.m., July 6, 2005.

7:30 a.m.–9 a.m., July 7, 2005.

Committee Meeting Times and Dates: 1 p.m.–6 p.m., July 5, 2005.

7:30 p.m.–9 p.m., July 5, 2005.

8:30 a.m.–5:30 p.m., July 6, 2005.

9 a.m.–4:15 p.m., July 7, 2005.

4:15 p.m.–5:45 p.m., July 7, 2005.

Place: Chase Park Plaza Hotel, 212-232 N. Kingshighway Blvd., St. Louis, Missouri 63108, telephone: 314-633-1000, fax: 314-633-1144.

Status: Open to the public, limited only by the space available. The meeting space accommodates approximately 200 people.

Background: The ABRWH was established under the Energy Employees Occupational Illness Compensation Program Act (EEOICPA) of 2000 to advise the President, delegated to the Secretary of Health and Human Services (HHS), on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Board include providing advice on the development of probability of causation guidelines which have been promulgated by HHS as a final rule, advice on methods of dose reconstruction which have also been promulgated by HHS as a final rule, advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program, and advice on petitions to add classes of workers to the Special Exposure Cohort (SEC). In December 2000, the President delegated responsibility for funding, staffing, and operating the Board to HHS, which subsequently delegated this

authority to the CDC. NIOSH implements this responsibility for CDC. The charter was issued on August 3, 2001, and renewed on August 3, 2003.

Purpose: This board is charged with (a) providing advice to the Secretary, HHS on the development of guidelines under Executive Order 13179; (b) providing advice to the Secretary, HHS on the scientific validity and quality of dose reconstruction efforts performed for this Program; and (c) upon request by the Secretary, HHS, advise the Secretary on whether there is a class of employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is reasonable likelihood that such radiation doses may have endangered the health of members of this class.

Matters to be Discussed: Agenda for this meeting will focus on comments by Members of Congress; Review of the Draft Minutes; Bethlehem Steel Technical Basis Document; Y-12 Site Profile; Y-12 SEC Petition; Board Discussion of Y-12 SEC Petition; Iowa Army Ammunition Plant (IAAP) SEC Petition; Board Discussion of IAAP SEC Petition; Mallinckrodt Site Profile; Mallinckrodt SEC Petition; Board Discussion of Mallinckrodt SEC Petition; Policy Issues related to SEC Petitions; SC&A Task III/Workbook Issues; Report on the review of the first 20 Dose Reconstructions; Report on the review of the second 18 Dose Reconstructions; SC&A Contract Issues; Board Discussion; Program Updates; and Science Issues. There will be an evening general public comment period scheduled for July 5, 2005 and one on the afternoon on July 7. Summaries of the petitions for designation of classes of employees at Mallinckrodt, IAAP, and the Y-12 Plant as members of the SEC and the NIOSH findings from evaluating the petitions that will be considered are as follows: Mallinckrodt Chemical Company, Destrehan Street Plant, St. Louis, Missouri, the entire uranium division, 1942-1957. The NIOSH SEC Petition Evaluation Report and Supplement for Mallinckrodt 1949-1957 finds sufficient scientific and technical basis to estimate radiation doses.

IAAP, Line 1, Burlington, Iowa, 1947-1974. The NIOSH SEC Petition Evaluation Report finds it is not feasible to estimate radiation doses potentially incurred by radiographers with sufficient accuracy from May 1948 to March 1949.

Y-12 Plant, Oak Ridge, Tennessee, Control Operators, January 1944 through December 1945. The NIOSH SEC Petition Evaluation Report finds it is not feasible to estimate radiation doses with sufficient accuracy for employees who worked in uranium enrichment operations or other radiological processes at the Y-12 facility from March 1943 through December 1947.

The agenda is subject to change as priorities dictate.

In the event an individual cannot attend, written comments may be submitted. Any written comments received will be provided at the meeting and should be submitted to the contact person below well in advance of the meeting.

Contact Person for More Information: Dr. Lewis V. Wade, Executive Secretary, NIOSH,

CDC, 4676 Columbia Parkway, Cincinnati, Ohio 45226, telephone (513) 533-6825, fax (513) 533-6826.

Due to programmatic issues that had to be resolved, the **Federal Register** notice is being published less than fifteen days before the date of the meeting.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: June 16, 2005.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 05-12292 Filed 6-21-05; 8:45 am]

BILLING CODE 4163-19-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2005D-0219]

Guidance for Industry: General Principles for Evaluating the Safety of Compounds Used in Food-Producing Animals; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a revised guidance for industry entitled "General Principles for Evaluating the Safety of Compounds Used in Food-Producing Animals (GFI #3)." This version of the guidance replaces the version that was made available in July 1994. This has been revised to remove outdated information on toxicological testing and to provide references to other available guidance on the topic. In addition, the document has been revised to address minor formatting issues.

DATES: Submit written or electronic comments on agency guidances at any time.

ADDRESSES: Submit written requests for single copies of the guidance to the Communications Staff (HFV-12), Center for Veterinary Medicine, Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855. Send one self-addressed adhesive label to assist that office in processing your requests.

Submit written comments on the guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit

electronic comments to <http://www.fda.gov/dockets/ecomments>. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the guidance document.

FOR FURTHER INFORMATION CONTACT:

Mark M. Robinson, Center for Veterinary Medicine (HFV-150), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-5282, e-mail: mrobinson@cvm.fda.gov.

SUPPLEMENTARY INFORMATION:

I. Background

FDA published the guidance for industry entitled "General Principles for Evaluating the Safety of Compounds Used in Food-Producing Animals (GFI #3)" in July 1994. Since that time, FDA has published a number of guidance documents in its participation with International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) that provide recommendations on toxicological testing of compounds used in food-producing animals. This version of guidance #3 replaces the version that was made available in July 1994. The guidance has been updated to remove outdated information on toxicological testing and refers the reader to the relevant Center for Veterinary Medicine/VICH guidance documents. In addition, the document was revised to address minor formatting issues including correcting an error in the numbering of the guidance sections.

II. Significance of Guidance

This document is being revised as a level 2 guidance consistent with FDA's good guidance practices regulation (21 CFR 10.115.) The guidance represents the agency's current thinking on the subject matter. The document does not create or confer any rights for or on any person and will not operate to bind FDA or the public. Alternative methods may be used as long as they satisfy the requirements of the applicable statutes and regulations.

III. Comments

As with all of FDA's guidances, the public is encouraged to submit written or electronic comments pertinent to this guidance. FDA will periodically review the comments in the docket and, where appropriate, will amend the guidance. The agency will notify the public of any such amendments through a notice in the **Federal Register**.

Interested persons may submit to the Division of Dockets Management (see **ADDRESSES**) written or electronic comments regarding this document.